StenoCare says France submits medical cannabis reimbursement decree for top court review
Reuters2026/08/07 06:02- StenoCare said France has submitted a draft decree on medical cannabis evaluation, pricing, and reimbursement to the Conseil d’État on July 2, 2026.
- Management framed the move as a key step toward a permanent French medical cannabis framework, with reimbursement seen as critical for market viability.
- The company said submission is not final approval; the decree still needs legal review, formal adoption, and publication before applications can open.
- StenoCare reiterated its ASTRUM 10-10 oil is positioned for the planned framework, with product approvals expected to require French-specific dossiers.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 8,222 shares for $98,730.32
Cang (CANG.US) Q2 total revenue fell about 50% quarter-on-quarter; mined 656 bitcoins
Cango announced its financial results for the second quarter of 2026.
Trump boasts "US economy can grow by 20%", says the Federal Reserve should not raise rates because of this
US President Trump, while announcing an agreement in the Oval Office aimed at lowering prescription drug prices, stated that the US economy could grow at a rate of 14%, 15%, 16%, or even 20%, emphasizing that such rapid growth should not prompt the Federal Reserve to raise interest rates.
Zcash Price Targets $1800 as Privacy Demand Fuels Rally
Crypto prices
More
